𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance

✍ Scribed by Steven Jong; Jan G. Zijlstra; Nanno H. Mulder; Elisabeth G. E. Vries

Publisher
Springer
Year
1991
Tongue
English
Weight
425 KB
Volume
28
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of an inducible anti-sense c-myc
Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line
✍ Robert C.A.M. Van Waardenburg; Coby Meijer; Herman Burger; Kees Nooter; Elisabet 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 151 KB 👁 2 views

## Small -cell-lung-cancer (SCLC) is characterized by rapid development of resistance to cytotoxic agents, such as cisplatin (cDDP) and anthracyclines. c-myc over-expression is one of the reported genetic alterations in this tumor. Amplification of the c-myc gene in this and other cancers is often

A study of cross-resistance pattern and
A study of cross-resistance pattern and expression of molecular markers of multidrug resistance in a human small-cell lung-cancer cell line selected with doxorubicin
✍ Rosanna Supino; Monica Binaschi; Giovanni Capranico; Romolo A. Gambetta; Elena S 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 920 KB

## Abstract A doxorubicin‐resistant variant of the human small‐cell lung‐cancer cell line N592 was selected by __in vitro__ continuous exposure to increasing drug concentrations. The aim of this study was to examine the cross‐resistance pattern, cellular pharmacokinetics of doxorubicin and expressi

A study of human small-cell lung carcino
A study of human small-cell lung carcinoma (hsclc) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (cddp) resistance
✍ G. A. P. Hospers; C. Meuer; L. De Leij; D. R. A. Uges; N. H. Mulder; E. G. E. De 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 French ⚖ 687 KB

The cisplatin(CDDP)-resistant cell line GLC,-CDDP shows a variety of differences from the parent line GLC,. The aim of this study was to determine which of the observed changes correlated with the degree of resistance and was therefore relevant to the phenomenon of CDDP resistance. For these experim

Effect of novobiocin on cisplatin cytoto
Effect of novobiocin on cisplatin cytotoxicity and dna interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line
✍ Steven De Jong; Hetty Timmer-Bosscha; Elisabeth G. E. De Vries; Nanno H. Mulder 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 948 KB

## Abstract Studies were performed to determine whether novobiocin can be used to enhance cisplatin (CDDP) cytotoxicity in a human small‐cell lung carcinoma cell line, GLC~4~/CDDP, resistant to CDDP. Continuous incubation with novobiocin enhanced the cytotoxicity of CDDP treatment 1.9‐fold in the p

A lack of detectable modification of top
A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance
✍ Bridget T. Hill; Richard D. H. Whelan; Louise K. Hosking; Sharon A. Shellard; Mi 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 French ⚖ 471 KB

## Abstract Etoposide (VP‐16) resistance is expressed following __in vitro__ exposure of HN‐1 and MCF‐7 human tumor cells to the drug itself or to fractionated × irradiation. VP‐16‐selected sublines prove cross‐resistant to Adriamycin, amsacrine and actinomycin D, whilst X‐ray‐pretreated sublines s

A truncated cytoplasmic topoisomerase II
A truncated cytoplasmic topoisomerase IIα in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34
✍ Shelagh E.L. Mirski; Kathryn E. Sparks; Qiang Yu; Alexander J. Lang; Nidhi Jain; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 131 KB

To study the problem of acquired resistance to widely used anti-cancer drugs that target the 170 kDa topoisomerase IIalpha (topo IIalpha), a drug-resistant human small-cell lung cancer cell line, H209/VP, was selected in VP-16. H209/VP cells express reduced levels of the 170 kDa topo IIalpha that is